Citadel Advisors
BCLI

Citadel Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Citadel Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,193
Closed -$7.58K – 14496
2024
Q3 		$7.58K Sell
2,193
-474
-18% -$2.24K ﹤0.01% 13355
2024
Q2 		$13.5K Sell
2,667
-693
-21% -$5.2K ﹤0.01% 12939
2024
Q1 		$28.5K Sell
3,360
-1,573
-32% -$8.65K ﹤0.01% 12742
2023
Q4 		$20.2K Sell
4,933
-3,667
-43% -$11K ﹤0.01% 12608
2023
Q3 		$25.8K Buy
8,600
+6,027
+234% +$137K ﹤0.01% 12405
2023
Q2 		$79.5K Sell
2,573
-1,794
-41% -$74.3K ﹤0.01% 11258
2023
Q1 		$216K Sell
4,367
-4,246
-49% -$123K ﹤0.01% 10045
2022
Q4 		$212K Buy
8,613
+1,240
+17% +$46.4K ﹤0.01% 10022
2022
Q3 		$489K Buy
7,373
+1,086
+17% +$54.5K ﹤0.01% 8497
2022
Q2 		$260K Buy
6,287
+1,780
+39% +$80.2K ﹤0.01% 10131
2022
Q1 		$227K Sell
4,507
-5,506
-55% -$270K ﹤0.01% 11220
2021
Q4 		$601K Buy
10,013
+466
+5% +$22.9K ﹤0.01% 9219
2021
Q3 		$473K Sell
9,547
-1,066
-10% -$56.1K ﹤0.01% 10004
2021
Q2 		$605K Sell
10,613
-2,514
-19% -$134K ﹤0.01% 9595
2021
Q1 		$754K Sell
13,127
-1,320
-9% -$99.7K ﹤0.01% 8781
2020
Q4 		$981K Sell
14,447
-1,613
-10% -$220K ﹤0.01% 6829
2020
Q3 		$4.08M Buy
16,060
+4,407
+38% +$903K ﹤0.01% 3461
2020
Q2 		$1.96M Buy
11,653
+3,966
+52% +$428K ﹤0.01% 4621
2020
Q1 		$535K Buy
7,687
+5,054
+192% +$394K ﹤0.01% 6357
2019
Q4 		$169K Buy
+2,633
New +$153K ﹤0.01% 8295
2018
Q4 		– Sell
-1,140
Closed -$65K – 9093
2018
Q3 		$65K Sell
1,140
-493
-30% -$29.8K ﹤0.01% 8736
2018
Q2 		$96K Buy
+1,633
New +$96.1K ﹤0.01% 8257
2017
Q4 		– Sell
-720
Closed -$44K – 7952
2017
Q3 		$44K Sell
720
-1,420
-66% -$91.9K ﹤0.01% 7209
2017
Q2 		$134K Buy
+2,140
New +$132K ﹤0.01% 6798

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BCLI Position: Q3 2023 in Review

Citadel Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 2,730 shares — an estimated $62.1K sold.

Citadel Advisors first reported a position in BCLI in Q1 2016 and held it in 17 quarters. The position peaked at $195K in Q2 2021. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • Citadel Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 2,730 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $62.1K.
  • Citadel Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2016 and held it in 17 quarters.
  • Citadel Advisors's BRAINSTORM CELL THERAPUTC position peaked at $195K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.